Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Precursor Cell Lymphoblastic Leukemia-lymphoma
Interventions
DRUG

Ixazomib

Ixazomib intravenous injection in combination with reduction chemotherapy.

Trial Locations (7)

8035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

10065

Memorial Sloan Kettering Cancer Center, New York

14004

C.H. Regional Reina Sofia, Córdoba

28046

Hospital Universitario La Paz, Madrid

38105

St Jude Children's Research Hospital, Memphis

39216

University of Mississippi Medical Center, Jackson

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY